News Discover the latest news stories, blog posts and publications from Cobra's expert team. You are here: Home News Toggle filters Year: All Years 2018 2017 2016 2015 2014 2013 2012 2011 or Month: All Months January February March April May June July August September October November December or Type: All Categories DNA Fill Finish General Proteins Technologies Viral Vectors Showing posts in the category 'DNA'. Show all posts Cobra Biologics and Symbiosis Awarded £1.9m ($2.5m USD) Innovate UK Grant DNA, Gene Therapy, Viral Vectors Funding will be used to develop world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy Links & Downloads: Cobra Articles DNA, Fill Finish, Gene Therapy, Proteins, Technologies, Viral Vectors A selection of links and downloadable magazine articles Cobra Expansion Video Blog DNA, Gene Therapy, Viral Vectors As We Embark On A £15m / 165m SEK / $19m Gene Therapy Manufacturing Operations Expansion Cobra Biologics Embarks On £15m (165m SEK) Gene Therapy Manufacturing Operations Expansion DNA, Gene Therapy, Viral Vectors Capacity increase in response to customer demand for DNA and viral vector production Advanced Therapies Manufacturing Taskforce DNA Cobra supports the objectives and, as part of our strategy for growth and expansion, will be looking closely to ensure that the UK does becomes a critical manufacturing centre for... Cobra and Touchlight Collaborate on Production of Next Generation DNA Constructs DNA Optimising the manufacture of AAV vectors to support gene therapy and regenerative medicine Cobra and Lancaster partnership helps unravel new analytical tool for DNA topology DNA Lorna Ashton from Lancaster University working with Cobra Biologics to assess a novel method for determining the topology of plasmid DNA. BLOG: Fit for Purpose DNA Processes - Interesting dilemas from a manufacturing perspective BLOG: Expanding DNA Market DNA In the last 2-3 years there has been a very marked increase in interest in the use of plasmid DNA. Cobra Biologics and BioCancell Announce Agreement to Manufacture Promising Cancer Therapy Drug DNA Cobra Biologics and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.